Portfolio Receipts growth of 12% to $608 million; Royalty Receipts growth of 11%
Net cash provided by operating activities of $658 million
Raising full year 2024 guidance: Portfolio Receipts expected to be $2,700 to $2,775 million

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the second quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts.

"We delivered double-digit growth in Portfolio Receipts in the second quarter of 2024, ahead of our guidance for the quarter, and are delighted to raise our full year guidance," said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. "Our performance in the first half of the year extends our track record of strong growth since our IPO. We also had a very active quarter for capital deployment, announcing over $2 billion of investments across six therapies as we expanded partnerships with Cytokinetics, PTC Therapeutics and Agios. In addition, reflecting our attractive fundamental outlook, we continued to repurchase our Class A ordinary shares as part of our balanced capital allocation strategy. Lastly, as we anticipated, 2024 is proving to be an event-rich year for our exciting development-stage pipeline with positive clinical updates on two key therapies in our portfolio. Looking ahead, we continue to have a robust deal pipeline and remain highly confident in our ability to deliver attractive, compounding growth over the long-term."

Double-digit growth for Portfolio Receipts and Royalty Receipts in the second quarter of 2024

Royalty Receipts grew 11% to $605 million, driven by strong portfolio performance particularly from the cystic fibrosis franchise, Trelegy, Tremfya and incremental royalties on Evrysdi.
Portfolio Receipts increased 12% to $608 million, primarily driven by the same royalties noted above.

Capital Deployment of approximately $2 billion in 2024, including cash to be paid for Voranigo (vorasidenib)

Acquired royalties on Servier's Voranigo, a first-in-class targeted therapy in IDH-mutant glioma.
Purchased incremental royalties on Roche's Evrysdi for spinal muscular atrophy.
Provided Cytokinetics with diversified capital, adding incremental royalty on aficamten for hypertrophic cardiomyopathy.

Positive clinical updates for the development-stage royalty portfolio

Johnson and Johnson announced positive Phase 3 results for seltorexant in major depressive disorder with insomnia symptoms and for Tremfya in Crohn's disease, including demonstrating superiority versus Stelara.

Raising financial guidance for full year 2024 (excludes contribution from future transactions)

Royalty Pharma now expects 2024 Portfolio Receipts to be between $2,700 million and $2,775 million (previously between $2,600 million and $2,700 million).
2024 Portfolio Receipts guidance includes expected year/year growth in Royalty Receipts of 9% to 12% (previous guidance of 5% to 9% year/year growth).

Financial & Liquidity Summary
	Three Months Ended June 30,
	(unaudited)
*($ and shares in millions)*	2024	2023	Change
Portfolio Receipts	608	545	12	%
Net cash provided by operating activities	658	608	8	%
Adjusted EBITDA (non-GAAP)*	560	498	13	%
Portfolio Cash Flow (non-GAAP)*	574	516	11	%
Weighted average Class A ordinary shares outstanding - diluted	597	606	(1	)%

*See "Liquidity and Capital Resources" section. Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures calculated in accordance with the credit agreement.

Portfolio Receipts Highlights
			Three Months Ended June 30,
			(unaudited)
*($ in millions)*			2024	2023	Change
Products:	Marketers:	Therapeutic Area:
Cystic fibrosis franchise	Vertex	Rare disease	195	170	15	%
Tysabri	Biogen	Neuroscience	64	70	(8	)%
Imbruvica	AbbVie, J&J	Cancer	49	52	(5	)%
Trelegy	GSK	Respiratory	48	37	32	%
Xtandi	Pfizer, Astellas	Cancer	39	33	16	%
Promacta	Novartis	Hematology	30	32	(4	)%
Tremfya	Johnson & Johnson	Immunology	30	22	34	%
Evrysdi	Roche	Rare disease	25	13	91	%
Cabometyx/Cometriq	Exelixis, Ipsen, Takeda	Cancer	17	15	9	%
Trodelvy	Gilead	Cancer	10	8	37	%
Spinraza	Biogen	Rare disease	10	13	(23	)%
Erleada	Johnson & Johnson	Cancer	9	5	72	%
Orladeyo	BioCryst	Rare disease	9	7	30	%
Nurtec ODT/Zavzpret	Pfizer	Neuroscience	4	4	10	%
Other products⁽⁵⁾			66	65	2	%
Royalty Receipts			605	545	11	%
Milestones and other contractual receipts			3	—	n/a
Portfolio Receipts			608	545	12	%

Amounts shown in the table may not add due to rounding.

Royalty Receipts was $605 million in the second quarter of 2024, an increase of 11% compared to $545 million in the second quarter of 2023, primarily driven by strong growth from the cystic fibrosis franchise, Trelegy, Tremfya and incremental royalties acquired on Evrysdi in October 2023.

Portfolio Receipts was $608 million in the second quarter of 2024, an increase of 12% compared to $545 million in the second quarter of 2023, primarily driven by the same Royalty Receipts increases noted above.

Liquidity and Capital Resources

Royalty Pharma's liquidity and capital resources are summarized below:

As of June 30, 2024, Royalty Pharma had cash and cash equivalents of $1.8 billion and total debt with principal value of $7.8 billion.

In June 2024, Royalty Pharma issued $1.5 billion of senior unsecured notes ("2024 Notes") with a weighted average coupon rate of 5.5%. Interest on the 2024 Notes is payable semi-annually in arrears on March 2 and September 2 of each year. The first interest payment date will be March 2, 2025. As of June 30, 2024, Royalty Pharma had total debt with a weighted-average duration of approximately 13 years and an attractive weighted-average cost of debt of 3.1%.

During the second quarter of 2024, Royalty Pharma repurchased approximately three million Class A ordinary shares for $84 million. Year-to-date (through August 7, 2024), Royalty Pharma has repurchased approximately four million Class A ordinary shares for $115 million. The weighted-average number of diluted Class A ordinary shares outstanding for the second quarter of 2024 was 597 million as compared to 606 million for the second quarter of 2023.

Liquidity Summary
	Three Months Ended June 30,
	(unaudited)
*($ in millions)*	2024		2023
Portfolio Receipts	608		545
Payments for operating and professional costs	(48	)	(47	)
Adjusted EBITDA (non-GAAP)	560		498
Interest received, net	14		18
Portfolio Cash Flow (non-GAAP)	574		516

Amounts may not add due to rounding.

Adjusted EBITDA (non-GAAP) was $560 million in the second quarter of 2024. Adjusted EBITDA is calculated as Portfolio Receipts minus payments for operating and professional costs.
Portfolio Cash Flow (non-GAAP) was $574 million in the second quarter of 2024. Portfolio Cash Flow is calculated as Adjusted EBITDA minus interest paid or received, net. This measure reflects the cash generated by Royalty Pharma's business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases, or utilized for other discretionary investments.

Refer to Table 4 for Royalty Pharma's reconciliation of each non-GAAP measure to the most directly comparable GAAP financial measure, net cash provided by operating activities.

Royalty Pharma announced new transactions of up to approximately $2.0 billion in the second quarter of 2024, which includes upfront payments and potential future milestones. Capital Deployment reflects cash payments during the period for new and previously announced transactions. Capital Deployment was $951 million in the second quarter of 2024, consisting primarily of the acquisition of royalties on frexalimab, the acquisition of additional royalties on Evrysdi, as well as the expanded strategic funding collaboration with Cytokinetics. Royalty Pharma will also pay Agios $905 million following the FDA approval of Voranigo (vorasidenib).

The table below details Capital Deployment by category:

Capital Deployment
	Three Months Ended June 30,				Six Months Ended June 30,
*($ in millions)*	2024		2023		2024		2023
Acquisitions of financial royalty assets	(729	)	(60	)	(815	)	(662	)
Development-stage funding payments - ongoing	(1	)	(1	)	(1	)	(1	)
Purchases of available for sale debt securities	(150	)	—		(150	)	—
Milestone payments	(50	)	—		(50	)	(12	)
Investments in equity method investees	(4	)	(3	)	(11	)	(7	)
Acquisitions of other financial assets	(18	)	—		(18	)	—
Contributions from legacy non-controlling interests - R&D	0		0		0		0
Capital Deployment	(951	)	(64	)	(1,044	)	(682	)

Amounts may not add due to rounding.

Recent Transactions

During 2024, Royalty Pharma announced new transactions of up to approximately $2.0 billion. Announced transactions amount reflects the entire amount of capital committed for new transactions during the year, including potential future milestones.

Recent transactions include:

In June 2024, PTC Therapeutics exercised its option to sell approximately half of its royalty retained on Roche's Evrysdi, an approved product for the treatment of spinal muscular atrophy, for approximately $242 million. This option arose from the Evrysdi royalty transaction with PTC that was announced in October 2023, in which Royalty Pharma acquired additional royalties on Evrysdi for $1 billion. PTC has an option to sell the remainder of its retained royalty on Evrysdi for up to approximately $250 million, less royalties received, until December 31, 2025.
In May 2024, Royalty Pharma announced a transaction to acquire a royalty interest in Voranigo (vorasidenib) from Agios Pharmaceuticals for an upfront payment of $905 million. The transaction was contingent upon FDA approval which was subsequently granted on August 6, 2024.
In May 2024, Royalty Pharma expanded its strategic funding collaboration with Cytokinetics, Incorporated ("Cytokinetics") to provide up to $575 million, including $250 million in upfront payments, in exchange for royalties and fixed payments.
In May 2024, Royalty Pharma acquired royalties and milestones on frexalimab, which was owned by ImmuNext, Inc., for approximately $525 million, including estimated transaction costs. Royalty Pharma is entitled to receive royalties on annual worldwide net sales of frexalimab and milestones related to the achievement of certain commercial and regulatory events. Frexalimab, which is in development by Sanofi, is a second generation anti-CD40 ligand monoclonal antibody. Frexalimab is being evaluated in Phase 3 clinical studies for the treatment of multiple sclerosis and is in Phase 2 clinical studies for systemic lupus erythematosus and Type 1 Diabetes.

The information in this section should be read together with Royalty Pharma's reports and documents filed with the SEC at www.sec.gov and the reader is also encouraged to review all other press releases and information available in the Investors section of Royalty Pharma's website at www.royaltypharma.com.

Key Developments Relating to the Portfolio

The key developments related to Royalty Pharma's royalty interests are discussed below based on disclosures from the marketers of the products.

Voranigo (vorasidenib)	In August 2024, Servier announced the FDA approval of Voranigo, a first-in-class targeted therapy for patients with isocitrate dehydrogenase 1 and 2 (IDH1/2) mutant diffuse glioma. Following this approval, Royalty Pharma will pay $905 million upfront in exchange for a 15% royalty on annual U.S. net sales of Voranigo up to $1 billion and a 12% royalty on annual U.S. net sales greater than $1 billion.
BCX10013	In August 2024, BioCryst announced that it plans to discontinue development of its oral Factor D inhibitor, BCX10013, as the level of clinical activity observed was less than other therapies on the market.
Trodelvy	In May 2024, Gilead announced that the confirmatory Phase 3 TROPiCS-04 study evaluating Trodelvy versus single-agent chemotherapy in patients with locally advanced or metastatic urothelial cancer did not meet the primary endpoint of overall survival. Gilead is continuing to analyze the data and will discuss the results and next steps with the FDA. In the United States, Trodelvy has an accelerated approval in this indication and continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials, including the TROPiCS-04 study.
Tremfya	In May 2024, Johnson and Johnson announced the first Phase 3 results for Tremfya in adult patients with moderate to severely active Crohn's disease, which demonstrated superiority versus placebo and Stelara. Data showed that both maintenance doses of Tremfya met the composite co-primary endpoints compared to placebo in each individual study. In results versus Stelara, both doses of Tremfya demonstrated statistically significant and clinically meaningful differences on all prespecified pooled endoscopic endpoints. In May 2024, Johnson and Johnson announced positive Phase 3 results for Tremfya in patients with moderate to severely active Crohn's disease with inadequate response/intolerance to conventional therapies and/or biologics. Johnson and Johnson submitted a supplemental Biologics License Application to the FDA seeking approval of Tremfya for Crohn's disease and an application to the European Medicines Agency for ulcerative colitis and Crohn's disease.
Cystic fibrosis franchise	In May 2024, Vertex announced that it submitted a New Drug Application and Marketing Authorization Application for the new triple combination therapy to the FDA and the European Medicines Agency, respectively, for approval. This followed positive Phase 3 results for the new triple combination therapy in February 2024. In April 2024, Vertex announced that the European Commission had granted approval for the label expansion of Kalydeco for the treatment of infants down to one month of age with cystic fibrosis (CF) who have certain mutations in the CF transmembrane conductance regulator gene.
Xtandi	In April 2024, Astellas Pharma announced the European Commission approved a label extension for Xtandi as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer who are unsuitable for salvage-radiotherapy.
Seltorexant	In May 2024, Johnson and Johnson announced positive results from the pivotal Phase 3 MDD3001 clinical trial evaluating the efficacy and safety of seltorexant as an adjunctive treatment in patients with major depressive disorder (MDD) with insomnia symptoms. The study achieved all primary and secondary endpoints, with seltorexant demonstrating both a statistically significant and clinically meaningful improvement in depressive symptoms, and improved sleep disturbance outcomes, in patients who had a prior inadequate response to SSRI/SNRI antidepressants alone.
Pelabresib	In May 2024, Novartis announced that it met all tender offer conditions to acquire MorphoSys for €68 per share. The acquisition of MorphoSys by Novartis has been completed.
TEV-'749	In May 2024, Teva Pharmaceuticals announced positive efficacy results from its Phase 3 trial evaluating TEV-'749, a once monthly subcutaneous long-acting injection of olanzapine, in adult patients with schizophrenia. Results demonstrated that TEV-'749 met its primary endpoint as measured by a change in the Positive and Negative Syndrome Scale (PANSS) total score from baseline after eight weeks compared to placebo. Additionally, no cases of Post-injection Delirium/Sedation Syndrome (PDSS) had been reported by that date, after administration of approximately 80% of the minimum target injection number.

2024 Financial Outlook

Royalty Pharma has provided guidance for full-year 2024, excluding transactions and borrowings announced after the date of this release, as follows:

	Provided August 8, 2024	Previous
Portfolio Receipts	$2,700 million to $2,775 million	$2,600 million to $2,700 million
Payments for operating and professional costs	8% to 9% of Portfolio Receipts	8% to 9% of Portfolio Receipts
Interest paid	$160 million	$160 million

The above Portfolio Receipts guidance includes expected Royalty Receipts growth of 9% to 12% in 2024.

Royalty Pharma's full-year 2024 guidance reflects a negligible estimated foreign exchange impact to Portfolio Receipts, assuming current foreign exchange rates prevail for 2024.

Total interest paid is based on the semi-annual interest payment schedule of Royalty Pharma's existing notes and is anticipated to be approximately $160 million in 2024. Interest paid is anticipated to be approximately $79 million in the third quarter of 2024 with a de minimis amount being recorded in the fourth quarter of 2024. The projection assumes no additional debt financing in 2024, including no drawdown on the revolving credit facility. In the second quarter of 2024, Royalty Pharma collected interest of $14 million on its cash and cash equivalents, which more than offset interest paid. In 2025, Royalty Pharma anticipates interest paid to be approximately $260 million, reflecting the aforementioned issuance of $1.5 billion of 2024 Notes.

Royalty Pharma today provides this guidance based on its most up-to-date view of its prospects. This guidance assumes no major unforeseen adverse events and excludes the contributions from transactions announced subsequent to the date of this press release. Furthermore, Royalty Pharma may amend its guidance in the event it engages in new royalty transactions which have a material near-term financial impact on the company.

Financial Results Call

Royalty Pharma will host a conference call and simultaneous webcast to discuss its second quarter 2024 results today at 8:00 a.m., Eastern Time. Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Novartis' Promacta, Pfizer's Nurtec ODT and Gilead's Trodelvy, and 16 development-stage product candidates.

Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This document contains statements that constitute "forward-looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma's strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," "expect," "may," "will," "would," "could" or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company's own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.

For further information, please reference Royalty Pharma's reports and documents filed with the U.S. Securities and Exchange Commission ("SEC") by visiting EDGAR on the SEC's website at www.sec.gov.

Portfolio Receipts

Portfolio Receipts is a key performance metric that represents our ability to generate cash from our portfolio investments, the primary source of capital that we can deploy to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. Royalty Receipts includes variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma.

Milestones and other contractual receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to legacy non-controlling interests, that are attributed to Royalty Pharma. Portfolio Receipts does not include proceeds from equity securities or proceeds from purchases and sales of marketable securities, neither of which are central to our fundamental business strategy.

Portfolio Receipts is calculated as the sum of the following line items from our GAAP statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from equity method investees less Distributions to legacy non-controlling interests - Portfolio Receipts, which represent contractual distributions of Royalty Receipts, milestones and other contractual receipts to RPSFT and the Legacy Investors Partnerships.

Use of Non-GAAP Measures

Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures that exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. Management believes that Adjusted EBITDA and Portfolio Cash Flow are important non-GAAP measures used to analyze liquidity because they are key components of certain material covenants contained within Royalty Pharma's credit agreement. Royalty Pharma cautions readers that amounts presented in accordance with the definitions of Adjusted EBITDA and Portfolio Cash Flow may not be the same as similar measures used by other companies or analysts. These non-GAAP liquidity measures have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of Royalty Pharma's results as reported under GAAP.

The definitions of Adjusted EBITDA and Portfolio Cash Flow used by Royalty Pharma are the same as the definitions in the credit agreement. Noncompliance with the interest coverage ratio, leverage ratio and Portfolio Cash Flow ratio covenants under the credit agreement could result in lenders requiring the company to immediately repay all amounts borrowed. If Royalty Pharma cannot satisfy these covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA and Portfolio Cash Flow are critical to the assessment of Royalty Pharma's liquidity.

Adjusted EBITDA and Portfolio Cash Flow are used by management as key liquidity measures in the evaluation of the company's ability to generate cash from operations. Management uses Adjusted EBITDA and Portfolio Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, debt repayments, dividends and other discretionary investments. Further, these non-GAAP liquidity measures help management, the audit committee and investors evaluate the company's ability to generate liquidity from operating activities.

The company has provided reconciliations of these non-GAAP liquidity measures to the most directly comparable GAAP financial measure, being net cash provided by operating activities in Table 4.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772

ir@royaltypharma.com

Royalty Pharma plc Condensed Consolidated Statements of Operations (unaudited) Table 1
	Three Months Ended June 30,
*($ in millions)*	2024		2023
Income and other revenues
Income from financial royalty assets	513		501
Other royalty income and revenues	24		37
Total income and other revenues	537		538
Operating expenses
Provision for changes in expected cash flows from financial royalty assets	212		241
Research and development funding expense	1		1
General and administrative expenses	55		48
Total operating expenses, net	268		289
Operating income	270		249
Other (income)/expense
Equity in (earnings)/losses of equity method investees	(2	)	1
Interest expense	49		47
Other expenses/(income), net	28		(150	)
Total other expenses/(income), net	75		(102	)
Consolidated net income before tax	194		351
Income tax expense	—		—
Consolidated net income	194		351
Net income attributable to non-controlling interests	92		124
Net income attributable to Royalty Pharma plc	102		228

Amounts may not add due to rounding.

Royalty Pharma plc Selected Balance Sheet Data (unaudited) Table 2
*($ in millions)*	As of June 30, 2024	As of December 31, 2023
Cash and cash equivalents	1,765	477
Total current and non-current financial royalty assets, net	14,640	14,827
Total assets	17,657	16,382
Long-term debt	7,602	6,135
Total liabilities	7,905	6,298
Total shareholders' equity	9,752	10,084

Royalty Pharma plc Condensed Consolidated Statements of Cash Flows (unaudited) Table 3
	Three Months Ended June 30,				Six Months Ended June 30,
*($ in millions)*	2024		2023		2024		2023
Cash flows from operating activities:
Cash collections from financial royalty assets	669		595		1,414		1,746
Cash collections from intangible royalty assets	0		0		14		1
Other royalty cash collections	23		40		50		60
Distributions from equity method investees	—		2		13		19
Interest received	14		19		21		35
Development-stage funding payments - ongoing	(1	)	(1	)	(1	)	(1	)
Payments for operating and professional costs	(48	)	(47	)	(109	)	(134	)
Interest paid	(1	)	(1	)	(80	)	(83	)
Net cash provided by operating activities	658		608		1,323		1,642
Cash flows from investing activities:
Distributions from equity method investees	4		—		9		35
Investments in equity method investees	(4	)	(3	)	(11	)	(7	)
Purchases of equity securities	(50	)	—		(50	)	—
Proceeds from equity securities	99		—		99		—
Purchases of available for sale debt securities	(150	)	—		(150	)	—
Proceeds from available for sale debt securities	3		—		4		—
Proceeds from sales and maturities of marketable securities	—		—		—		24
Acquisitions of financial royalty assets	(729	)	(60	)	(815	)	(662	)
Acquisitions of other financial assets	(18	)	—		(18	)	—
Milestone payments	(50	)	—		(50	)	(12	)
Other	2		—		2		—
Net cash used in investing activities	(893	)	(63	)	(980	)	(622	)
Cash flows from financing activities:
Distributions to legacy non-controlling interests - Portfolio Receipts	(92	)	(92	)	(180	)	(184	)
Distributions to continuing non-controlling interests	(31	)	(31	)	(63	)	(64	)
Dividends to shareholders	(95	)	(91	)	(189	)	(179	)
Repurchases of Class A ordinary shares	(80	)	(134	)	(80	)	(134	)
Contributions from legacy non-controlling interests - R&D	0		0		0		0
Contributions from non-controlling interests - other	1		1		2		4
Proceeds from issuance of long-term debt, net of discount	1,471		—		1,471		—
Debt issuance costs and other	(9	)	—		(9	)	—
Other	(9	)	—		(9	)	—
Net cash provided by/(used in) financing activities	1,157		(347	)	945		(557	)
Net change in cash and cash equivalents	922		197		1,288		462
Cash and cash equivalents, beginning of period	843		1,976		477		1,711
Cash and cash equivalents, end of period	1,765		2,173		1,765		2,173

Amounts may not add due to rounding.

Royalty Pharma plc GAAP to Non-GAAP Reconciliation (unaudited) Table 4
	Three Months Ended June 30,
*($ in millions)*	2024		2023
Net cash provided by operating activities (GAAP)	658		608
Adjustments:
Proceeds from available for sale debt securities⁽⁶⁾	3		—
Distributions from equity method investees⁽⁶⁾	4		—
Interest received, net⁽⁶⁾	(14	)	(18	)
Development-stage funding payments - ongoing	1		1
Distributions to legacy non-controlling interests - Portfolio Receipts⁽⁶⁾	(92	)	(92	)
Adjusted EBITDA (non-GAAP)	560		498
Interest received, net⁽⁶⁾	14		18
Portfolio Cash Flow (non-GAAP)	574		516

Amounts may not add due to rounding.

Royalty Pharma plc

Description of Approved Indications for Select Portfolio Therapies

Table 5

Cystic fibrosis franchise	Cystic fibrosis
Tysabri	Relapsing forms of multiple sclerosis
Imbruvica	Hematological malignancies and chronic graft versus host disease
Trelegy	Chronic obstructive pulmonary disease and asthma
Xtandi	Prostate cancer
Promacta	Chronic immune thrombocytopenia purpura and aplastic anemia
Tremfya	Plaque psoriasis and active psoriatic arthritis
Evrysdi	Spinal muscular atrophy
Cabometyx/Cometriq	Kidney, liver and thyroid cancer
Trodelvy	Breast and bladder cancer
Spinraza	Spinal muscular atrophy
Erleada	Prostate cancer
Orladeyo	Hereditary angioedema
Nurtec ODT/Zavzpret	Acute and preventative treatment of migraine

Notes

(1) Portfolio Receipts is a key performance metric that represents our ability to generate cash from our portfolio investments, the primary source of capital that we can deploy to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty Receipts and milestones and other contractual receipts. Royalty Receipts includes variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma ("Royalty Receipts"). Milestones and other contractual receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma. Portfolio Receipts does not include proceeds from equity securities or marketable securities, both of which are not central to our fundamental business strategy.

(2) Adjusted EBITDA is defined under the credit agreement as Portfolio Receipts minus payments for operating and professional costs. Operating and professional costs reflect Payments for operating and professional costs from the GAAP statements of cash flows. See GAAP to Non-GAAP reconciliation in Table 4.

(3) Portfolio Cash Flow is defined under the credit agreement as Adjusted EBITDA minus interest paid or received, net. See GAAP to Non-GAAP reconciliation in Table 4. Portfolio Cash Flow reflects the cash generated by Royalty Pharma's business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases or utilized for other discretionary investments.

(4) Capital Deployment is calculated as the summation of the following line items from our GAAP statements of cash flows: Investments in equity method investees, Purchases of available for sale debt securities, Acquisitions of financial royalty assets, Acquisitions of other financial assets, Milestone payments, Development-stage funding payments - ongoing, Development-stage funding payments - upfront and milestone less Contributions from legacy non-controlling interests - R&D.

(5) Other products primarily include Royalty Receipts on the following products: Cimzia, Crysvita, Emgality, Farxiga/Onglyza, IDHIFA, Lexiscan, Nesina, Prevymis, Soliqua and distributions from the Legacy SLP Interest, which is presented as Distributions from equity method investees on the GAAP statements of cash flows.

(6) The table below shows the line item for each adjustment and the direct location for such line item on the GAAP statements of cash flows.

Reconciling Adjustment	Statements of Cash Flows Classification
Interest received, net	Operating activities (Interest paid less Interest received)
Distributions from equity method investees	Investing activities
Proceeds from available for sale debt securities	Investing activities
Distributions to legacy non-controlling interests - Portfolio Receipts	Financing activities